Your session is about to expire
← Back to Search
Treatment for Transcatheter Aortic Valve Replacement (CAN-ACCESS Trial)
N/A
Recruiting
Led By Janarthanan Sathananthan, MBChB, MPH
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients undergoing elective transfemoral TAVR with the Evolut THV (Medtronic, Minneapolis, MN, USA).
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during tavr procedure
Awards & highlights
CAN-ACCESS Trial Summary
This trial is testing the best way to do a heart procedure after a specific type of heart valve implant.
Who is the study for?
This trial is for patients who are scheduled to undergo an elective transfemoral Transcatheter Aortic Valve Replacement (TAVR) using the Evolut THV device. Participants must provide written consent to be part of the study.Check my eligibility
What is being tested?
The study aims to identify the best methods and tools for engaging coronary arteries after implanting the Evolut THV, a heart valve replacement device, with a focus on aligning it properly during surgery.See study design
What are the potential side effects?
Since this trial focuses on techniques rather than medications, side effects may include typical surgical risks such as bleeding or infection at the catheter insertion site.
CAN-ACCESS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for a specific heart valve replacement through my thigh.
CAN-ACCESS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ during tavr procedure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during tavr procedure
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The ability to selectively engage and obtain diagnostic epicardial coronary angiography images from the right and left coronary ostia
Secondary outcome measures
Description of type of technique utilized to achieve selective coronary engagement.
Total contrast use (ml) from catheter insertion to selective coronary engagement.
Total fluoroscopic time (mins) from catheter insertion to selective coronary engagement.
+2 moreFind a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,418 Previous Clinical Trials
2,467,068 Total Patients Enrolled
MedtronicIndustry Sponsor
606 Previous Clinical Trials
828,615 Total Patients Enrolled
The Centre for Cardiovascular Innovation - Centre d'Innovation Cardiovasculaire (CCI-CIC)UNKNOWN
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants are partaking in this medical experiment?
"To execute this trial, Medtronic requires a total of 50 individuals meeting the study's criteria. The clinical sites chosen by the sponsor are Sunnybrook Health Sciences Centre in Toronto and UPMC Harrisburg in Pennsylvania."
Answered by AI
Is this trial currently seeking to enroll participants?
"Affirmative, the trial is currently recruiting according to clinicaltrials.gov's data. Starting on October 27th 2021 and last updated August 30th 2022, this research seeks 50 participants from 4 different sites."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger